Photo illusration: Axios. Photo: Courtesy of Citizens Capital Markets
Biotech has seen more than $25 billion in M&A over the past two weeks alone, putting 2026 on track for a strong year in biopharma, says Citizens Capital Markets head of biopharma David Kellman.
Why it matters: Investors are encouraged, with the XBI spiking 7% on Tuesday, the last day of Q1.
